We're very happy to announce that zoliflodacin met its primary endpoint in an unprecedented global pivotal phase 3 clinical trial 🤩
These positive findings offer hope for patients with #gonorrhoea.
W/ @innovivastx 👇
https://t.co/zPpzLS1x8w
#AMR
In collaboration with @ICMRDELHI, this study will collect and analyze data in 180 patients being treated for #infections caused by carbapenem-resistant organisms across 6 #hospitals in #India
We're very happy to announce the launch of our observational study in #India which will shed light on the management of #antibioticresistant infections in #hospitals 🏥
👉https://t.co/0QmWkiiC4m
Only one week to go till our live webinar. Join @obriensea @fjfranceschi, Sally Ellis and @LauraPiddock for an update on #GARDP's ongoing work to bring new antibiotic treatments for drug-resistant infections to all who need them. Register here: https://t.co/MMg1GlZoJh #AMR
Why are new #antibiotics like cefepime-taniborbactam needed? Serious bacterial infections are among the major causes of death for people in hospitals. #DrugResistance is making these infections increasingly difficult to treat. #StopSuperBugs#WakeUpToAMR
Delighted to host our partners as we plan the next steps for our children’s #antibiotics programme. 🦠🚼💊
Learn more about our work in this area and what we have planned for the future: https://t.co/dBGy65c5GT
Thanks to the Indian Council of Medical Research and all the fantastic participants for the excellent workshop on AMR related clinical trials and networks. #AMR @gardp_amr
The #GARDP team is taking time out during the next two days for strategic planning and team building.
We're excited to be working on the future treatments for antibiotic resistance infections! #WakeUpToAMR#5BY25
@WHOWPRO@fjfranceschi @PeterBeyer3 @LivLD@mling54 Our François Franceschi spoke today about the need for public-health-driven #antibiotic development. For us this means:
1) @WHO priority pathogens
2) Underserved populations & diseases
3) Indications currently ignored due to perceived
risk, challenges & lack of💵